Cardiac Risks of Melatonin
Melatonin is generally associated with minimal cardiac risk in most patients, with the most commonly reported cardiovascular effects being hypotension and hypertension at higher doses, though recent emerging evidence suggests potential concerns for arrhythmias and heart failure that warrant clinical awareness and monitoring in susceptible individuals.
Overview of Cardiovascular Safety Profile
According to American Academy of Sleep Medicine guidelines, melatonin is generally associated with a lack of reported serious adverse effects 1. The established cardiovascular effects include:
Documented Blood Pressure Effects
- Hypotension and hypertension have been reported, particularly at higher melatonin doses in healthy adults 1
- These same effects occur at lower doses in patients with relevant preexisting cardiovascular conditions 1
- The National Academy of Sciences review indicates short-term use of ≤10 mg/daily appears safe in healthy adults 1
Emerging Arrhythmia Concerns
Recent case reports and pharmacovigilance data reveal a more nuanced picture:
Bradycardia and Conduction Disturbances:
- A 2024 case report documented symptomatic bradycardia in a healthy 22-year-old male after ingesting 20 mg melatonin, which resolved spontaneously within hours 2
- A 2026 case report described atrioventricular block in a 63-year-old man taking 10 mg daily, with complete resolution after discontinuation 3
- Melatonin may induce cardiac vagal tone, affecting heart rate and mean arterial pressure 2
Counterbalancing Evidence:
- A 2025 pharmacovigilance analysis using FDA adverse event data found melatonin receptor agonists were negatively correlated with cardiac arrhythmias compared to benzodiazepine receptor agonists 4
- The reporting odds ratios showed protective associations: cardiac arrhythmias (ROR: 0.47), bradyarrhythmias (ROR: 0.20), and ventricular tachyarrhythmias (ROR: 0.05) 4
Heart Failure Signal
A concerning but unconfirmed association emerged from a 2025 American Heart Association conference abstract (not yet peer-reviewed):
- Reported increased risk of new-onset heart failure, HF hospitalization, and all-cause mortality with long-term melatonin use (≥1 year) in adults with insomnia 5
- However, a 2026 NHANES analysis found no significant association between recent melatonin use and prevalent cardiovascular disease or heart failure in a nationally representative sample 6
Proposed Mechanism (Speculative)
A hypothetical prolactin-mediated pathway has been proposed 5:
- Melatonin may increase prolactin release through hypothalamic dopaminergic modulation
- Excess prolactin could theoretically be cleaved to a cardiotoxic 16-kDa fragment in patients with oxidative stress
- This mechanism remains unproven and requires prospective validation
Potential Cardioprotective Effects
A 2026 meta-analysis of 14 randomized trials (1,027 participants) found:
- Melatonin significantly improved change in left ventricular ejection fraction (mean difference: 3.95 percentage points; 95% CI: 1.70-6.20) 7
- Most consistent benefit seen in coronary artery bypass grafting patients (mean difference: 4.65 percentage points) 7
- Suggested reduction in inflammatory and oxidative stress markers post-CABG 7
Clinical Recommendations
Patient Selection and Monitoring
Exercise caution in:
- Patients with pre-existing cardiac conduction abnormalities or bradycardia
- Those taking medications that affect heart rate (beta-blockers, calcium channel blockers) 8
- Patients on warfarin (case reports of interactions) 1
- Individuals with epilepsy 1
Dosing Considerations:
- Start with lower doses (0.5-3 mg) rather than higher doses (≥10 mg) to minimize cardiovascular effects 1
- The 2026 AASM guideline for shift work disorder suggests melatonin use but notes it may temporarily increase sleepiness and accident risk 9
- Use U.S. Pharmacopeial Convention Verified formulations for reliable dosing 1, 10
Monitoring Strategy
For patients initiating melatonin with cardiovascular risk factors:
- Document baseline heart rate and blood pressure
- Inquire about palpitations, dizziness, or syncope at follow-up
- Consider baseline ECG in patients with known conduction disease
- Advise patients to report new cardiovascular symptoms immediately
- For long-term use (>1 year), maintain heightened clinical vigilance for heart failure symptoms pending further evidence
Special Populations
The 2025 ICU guideline suggests melatonin administration in critically ill adults (conditional recommendation), noting it may reduce delirium prevalence with low risk of adverse events 11. However, this population requires continuous cardiac monitoring regardless.
Critical Knowledge Gaps
The evidence reveals significant uncertainty:
- Long-term cardiovascular safety data remain scarce 1
- Observational studies are highly vulnerable to confounding-by-indication, as insomnia itself is associated with cardiovascular risk 6
- The heart failure signal requires peer-reviewed validation and mechanistic confirmation 5, 6
- Optimal dosing, timing, and duration for cardiovascular safety are undefined 11
Bottom Line
Melatonin carries low but non-zero cardiac risk. The most established effects are dose-dependent blood pressure changes. Emerging case reports of bradycardia and conduction disturbances warrant clinical awareness, though large pharmacovigilance data suggest lower arrhythmia risk compared to benzodiazepines. The unconfirmed heart failure signal requires cautious interpretation pending peer review. Use the lowest effective dose, verify product quality, monitor cardiovascular symptoms, and maintain clinical vigilance in patients with pre-existing cardiac disease or those on interacting medications.